Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yong Chong Cao, the Chinese name for the fungus *Cordyceps militaris*, is a prominent agent in Traditional Chinese Medicine (TCM) often utilized as a therapeutic alternative to the rarer *Cordyceps sinensis*. It is primarily recognized for its potential in treating respiratory and renal conditions, particularly in patients exhibiting the TCM syndrome of lung and kidney qi deficiency. The therapeutic efficacy of Yong Chong Cao is attributed to a variety of bioactive compounds, most notably cordycepin (3'-deoxyadenosine), adenosine, and various polysaccharides. These components are thought to exert anti-inflammatory, antioxidant, and immunomodulatory effects. Clinical research, such as trial NCT03745261, has focused on its ability to reduce exacerbations and improve lung function (FEV1) and quality of life in patients with mild to severe Chronic Obstructive Pulmonary Disease (COPD).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yong Chong Cao.